These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 27801990)

  • 1. Inhibition of complement in Guillain-Barré syndrome: the ICA-GBS study.
    Davidson AI; Halstead SK; Goodfellow JA; Chavada G; Mallik A; Overell J; Lunn MP; McConnachie A; van Doorn P; Willison HJ
    J Peripher Nerv Syst; 2017 Mar; 22(1):4-12. PubMed ID: 27801990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of eculizumab in Guillain-Barré syndrome: A phase 3, multicenter, double-blind, randomized, placebo-controlled clinical trial.
    Kuwabara S; Kusunoki S; Kuwahara M; Yamano Y; Nishida Y; Ishida H; Kasuya T; Kupperman E; Lin Q; Frick G; Misawa S
    J Peripher Nerv Syst; 2024 Sep; 29(3):339-349. PubMed ID: 38987228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of eculizumab in Guillain-Barré syndrome: a multicentre, double-blind, randomised phase 2 trial.
    Misawa S; Kuwabara S; Sato Y; Yamaguchi N; Nagashima K; Katayama K; Sekiguchi Y; Iwai Y; Amino H; Suichi T; Yokota T; Nishida Y; Kanouchi T; Kohara N; Kawamoto M; Ishii J; Kuwahara M; Suzuki H; Hirata K; Kokubun N; Masuda R; Kaneko J; Yabe I; Sasaki H; Kaida KI; Takazaki H; Suzuki N; Suzuki S; Nodera H; Matsui N; Tsuji S; Koike H; Yamasaki R; Kusunoki S;
    Lancet Neurol; 2018 Jun; 17(6):519-529. PubMed ID: 29685815
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second IVIg course in Guillain-Barré syndrome patients with poor prognosis (SID-GBS trial): Protocol for a double-blind randomized, placebo-controlled clinical trial.
    Walgaard C; Jacobs BC; Lingsma HF; Steyerberg EW; Cornblath DR; van Doorn PA;
    J Peripher Nerv Syst; 2018 Dec; 23(4):210-215. PubMed ID: 30151941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial.
    Walgaard C; Jacobs BC; Lingsma HF; Steyerberg EW; van den Berg B; Doets AY; Leonhard SE; Verboon C; Huizinga R; Drenthen J; Arends S; Budde IK; Kleyweg RP; Kuitwaard K; van der Meulen MFG; Samijn JPA; Vermeij FH; Kuks JBM; van Dijk GW; Wirtz PW; Eftimov F; van der Kooi AJ; Garssen MPJ; Gijsbers CJ; de Rijk MC; Visser LH; Blom RJ; Linssen WHJP; van der Kooi EL; Verschuuren JJGM; van Koningsveld R; Dieks RJG; Gilhuis HJ; Jellema K; van der Ree TC; Bienfait HME; Faber CG; Lovenich H; van Engelen BGM; Groen RJ; Merkies ISJ; van Oosten BW; van der Pol WL; van der Meulen WDM; Badrising UA; Stevens M; Breukelman AJ; Zwetsloot CP; van der Graaff MM; Wohlgemuth M; Hughes RAC; Cornblath DR; van Doorn PA;
    Lancet Neurol; 2021 Apr; 20(4):275-283. PubMed ID: 33743237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Original research: Second IVIg course in Guillain-Barré syndrome with poor prognosis: the non-randomised ISID study.
    Verboon C; van den Berg B; Cornblath DR; Venema E; Gorson KC; Lunn MP; Lingsma H; Van den Bergh P; Harbo T; Bateman K; Pereon Y; Sindrup SH; Kusunoki S; Miller J; Islam Z; Hartung HP; Chavada G; Jacobs BC; Hughes RAC; van Doorn PA;
    J Neurol Neurosurg Psychiatry; 2020 Feb; 91(2):113-121. PubMed ID: 31586949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of intravenous immunoglobulin retreatment amongst Guillain-Barré syndrome patients who poorly responded to initial IVIG cycle: a systematic review.
    Prado MB; Adiao KJB; Turalde CWR; Dasig DA
    Acta Neurol Belg; 2024 Aug; 124(4):1237-1250. PubMed ID: 38553651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Prospective, Multicenter, Randomized Phase II Study to Evaluate the Efficacy and Safety of Eculizumab in Patients with Guillain-Barré Syndrome (GBS): Protocol of Japanese Eculizumab Trial for GBS (JET-GBS).
    Yamaguchi N; Misawa S; Sato Y; Nagashima K; Katayama K; Sekiguchi Y; Iwai Y; Amino H; Suichi T; Yokota T; Nishida Y; Kohara N; Hirata K; Nishiyama K; Yabe I; Kaida KI; Suzuki N; Nodera H; Tsuji S; Koike H; Kira JI; Hanaoka H; Kusunoki S; Kuwabara S;
    JMIR Res Protoc; 2016 Nov; 5(4):e210. PubMed ID: 27821382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Complement-Mediated Mechanism and Complement Inhibitors in Guillain-Barré Syndrome].
    Kuwahara M; Kusunoki S
    Brain Nerve; 2019 Jun; 71(6):581-587. PubMed ID: 31171755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial.
    van Koningsveld R; Schmitz PI; Meché FG; Visser LH; Meulstee J; van Doorn PA;
    Lancet; 2004 Jan; 363(9404):192-6. PubMed ID: 14738791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Corticosteroids for treating Guillain-Barré syndrome.
    Hughes RA; van der Meché FG
    Cochrane Database Syst Rev; 2000; (2):CD001446. PubMed ID: 10796795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Novel Therapeutic Interventions in Guillain-Barré Syndrome: Review and Future Perspective].
    Misawa S
    Brain Nerve; 2015 Nov; 67(11):1421-8. PubMed ID: 26560957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous immunoglobulin treatment for mild Guillain-Barré syndrome: an international observational study.
    Verboon C; Harbo T; Cornblath DR; Hughes RAC; van Doorn PA; Lunn MP; Gorson KC; Barroso F; Kuwabara S; Galassi G; Lehmann HC; Kusunoki S; Reisin RC; Binda D; Cavaletti G; Jacobs BC; ;
    J Neurol Neurosurg Psychiatry; 2021 Oct; 92(10):1080-1088. PubMed ID: 34103340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunoglobulin and Monoclonal Antibody Therapies in Guillain-Barré Syndrome.
    Rajabally YA
    Neurotherapeutics; 2022 Apr; 19(3):885-896. PubMed ID: 35648286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous immunoglobulin therapy for HIV-associated Guillain-Barré syndrome.
    Wang J; Zhang Y; Wang M; Ren Y; Tang M; Liu L; Zhou D
    Int Immunopharmacol; 2022 Nov; 112():109192. PubMed ID: 36155283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What's new in Guillain-Barré syndrome in 2007-2008?
    van Doorn PA
    J Peripher Nerv Syst; 2009 Jun; 14(2):72-4. PubMed ID: 19691528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy and mechanism of lymphoplasma exchange in the treatment of Guillain-Barre syndrome.
    Luo MC; Wang WF; Yin WF; Li Y; Li BJ; Duan WW; Zeng QM; Luo YB; Yang XS; Yang H
    Cell Mol Biol (Noisy-le-grand); 2017 Oct; 63(10):106-115. PubMed ID: 29096750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small volume plasma exchange for Guillain-Barré syndrome in resource-limited settings: a phase II safety and feasibility study.
    Islam B; Islam Z; Rahman S; Endtz HP; Vos MC; van der Jagt M; van Doorn PA; Jacobs BC; Mohammad QD
    BMJ Open; 2018 Aug; 8(8):e022862. PubMed ID: 30121613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnosis, treatment and prognosis of Guillain-Barré syndrome (GBS).
    van Doorn PA
    Presse Med; 2013 Jun; 42(6 Pt 2):e193-201. PubMed ID: 23628447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcomes of plasma exchange versus intravenous immunoglobulin for the treatment of Guillain-Barré Syndrome: A double-blind, randomized clinical trial.
    Haridy NA; Shehab MM; Khedr EM
    Restor Neurol Neurosci; 2023; 41(5-6):203-217. PubMed ID: 38217554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.